Toll-Like Receptor 3 as a Recurrence Risk Factor and a Potential Molecular Therapeutic Target in Colorectal Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065. doi:10.1038/nrdp.2015.65
   PubMed Web of Science ®Google Scholar
• Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–2114.e2105. doi:10.1053/j.gastro.2010.01.058
   PubMed Web of Science ®Google Scholar
• Tandon K, Imam M, Ismail BE, Castro F. Body mass index and colon cancer screening: the road ahead. World J Gastroenterol. 2015;21(5):1371–1376. doi:10.3748/wjg.v21.i5.1371
   Web of Science ®Google Scholar
• Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol. 2011;22(9):1958–1972. doi:10.1093/annonc/mdq653
   PubMed Web of Science ®Google Scholar
• Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology. 2015;148(6):1244–1260 e1216. doi:10.1053/j.gastro.2014.12.035
   PubMed Web of Science ®Google Scholar
• Watanabe T, Muro K, Ajioka Y, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23(1):1–34. doi:10.1007/s10147-017-1101-6
   PubMed Web of Science ®Google Scholar
• Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–3419. doi:10.1200/JCO.2004.05.063
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479–2516. doi:10.1093/annonc/mds236
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2015;109(1):1412 11–10. doi:10.1002/0471142735.im1412s109
   Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801. doi:10.1016/j.cell.2006.02.015
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045. doi:10.1146/annurev.iy.12.040194.005015
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–195. doi:10.1038/nature00858
   PubMed Web of Science ®Google Scholar
• Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425(6957):516–521. doi:10.1038/nature01991
   PubMed Web of Science ®Google Scholar
• Venereau E, Ceriotti C, Bianchi ME. DAMPs from cell death to new life. Front Immunol. 2015;6(422):422. doi:10.3389/fimmu.2015.00422
   Web of Science ®Google Scholar
• Sato Y, Goto Y, Narita N, Hoon DS. Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2009;2(Suppl 1):205–214. doi:10.1007/s12307-009-0022-y
   PubMedGoogle Scholar
• Dajon M, Iribarren K, Cremer I. Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword. Immunobiology. 2017;222(1):89–100. doi:10.1016/j.imbio.2016.06.009
   PubMed Web of Science ®Google Scholar
• Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008;27(2):218–224. doi:10.1038/sj.onc.1210904
   PubMed Web of Science ®Google Scholar
• Nihon-Yanagi Y, Terai K, Murano T, Matsumoto T, Okazumi S. Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancer. Cancer Immunol Immunother. 2012;61(1):71–77. doi:10.1007/s00262-011-1085-4
   Web of Science ®Google Scholar
• So EY, Ouchi T. The application of Toll like receptors for cancer therapy. Int J Biol Sci. 2010;6(7):675–681. doi:10.7150/ijbs.6.675
   Web of Science ®Google Scholar
• Eiro N, Gonzalez L, Gonzalez LO, et al. Study of the expression of toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer. J Clin Immunol. 2012;32(4):848–854. doi:10.1007/s10875-012-9666-3
   Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732–738. doi:10.1038/35099560
   PubMed Web of Science ®Google Scholar
• Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem. 2004;279(13):12542–12550. doi:10.1074/jbc.M310175200
   PubMed Web of Science ®Google Scholar
• Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006;176(8):4894–4901. doi:10.4049/jimmunol.176.8.4894
   PubMed Web of Science ®Google Scholar
• Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res. 2007;13(15 Pt 1):4565–4574. doi:10.1158/1078-0432.CCR-07-0274
   PubMed Web of Science ®Google Scholar
• Paone A, Starace D, Galli R, et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis. 2008;29(7):1334–1342. doi:10.1093/carcin/bgn149
   PubMed Web of Science ®Google Scholar
• Chew V, Tow C, Huang C, et al. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst. 2012;104(23):1796–1807. doi:10.1093/jnci/djs436
   PubMedGoogle Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi:10.1038/bmt.2012.244
   PubMed Web of Science ®Google Scholar
• Nojiri K, Sugimoto K, Shiraki K, et al. The expression and function of Toll-like receptors 3 and 9 in human colon carcinoma. Oncol Rep. 2013;29(5):1737–1743. doi:10.3892/or.2013.2322
   PubMed Web of Science ®Google Scholar
• Niedzielska I, Niedzielski Z, Tkacz M, et al. Toll-like receptors and the tendency of normal mucous membrane to transform to polyp or colorectal cancer. J Physiol Pharmacol. 2009;60(Suppl 1):65–71.
   PubMedGoogle Scholar
• Itatani Y, Kawada K, Inamoto S, et al. The role of chemokines in promoting colorectal cancer invasion/metastasis. Int J Mol Sci. 2016;17(5):643. doi:10.3390/ijms17050643
   PubMed Web of Science ®Google Scholar
• Sato K, Kuratsu J, Takeshima H, Yoshimura T, Ushio Y. Expression of monocyte chemoattractant protein-1 in meningioma. J Neurosurg. 1995;82(5):874–878. doi:10.3171/jns.1995.82.5.0874
   Web of Science ®Google Scholar
• Watanabe H, Miki C, Okugawa Y, Toiyama Y, Inoue Y, Kusunoki M. Decreased expression of monocyte chemoattractant protein-1 predicts poor prognosis following curative resection of colorectal cancer. Dis Colon Rectum. 2008;51(12):1800–1805. doi:10.1007/s10350-008-9380-7
   Web of Science ®Google Scholar
• Musha H, Ohtani H, Mizoi T, et al. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer. 2005;116(6):949–956. doi:10.1002/ijc.21135
   PubMed Web of Science ®Google Scholar
• Daster S, Eppenberger-Castori S, Hirt C, et al. High frequency of CD8 positive lymphocyte infiltration correlates with lack of lymph node involvement in early rectal cancer. Dis Markers. 2014;2014:792183. doi:10.1155/2014/792183
   Web of Science ®Google Scholar
• Kobayashi Y. The role of chemokines in neutrophil biology. Front Biosci. 2008;13:2400–2407. doi:10.2741/2853
   PubMed Web of Science ®Google Scholar
• Granot Z, Henke E, Comen EA, King TA, Norton L, Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 2011;20(3):300–314. doi:10.1016/j.ccr.2011.08.012
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572.
   PubMed Web of Science ®Google Scholar